Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010 Mar 25. 362(12):1071-81. [QxMD MEDLINE Link].
Mullen KD, Poordad F, Rossaro L, et al. Long term efficacy and survival in patients treated with the gut-selective antibiotic rifaximin (550 mg BID) for the maintenance of remission from overt hepatic encephalopathy. Gastroenterol Hepatol. 2011. 7(6 Suppl 9):1-15.
McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev. 2011. (11):CD008716. [QxMD MEDLINE Link].
Agrawal A, Sharma BC, Sharma P, Sarin SK. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol. 2012 Jul. 107(7):1043-50. [QxMD MEDLINE Link].
Weiss N, Tripon S, Lodey M, et al, for the Brain-Liver Pitie-Salpetriere Study Group (BLIPS). Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study. Fundam Clin Pharmacol. 2018 Apr. 32(2):209-15. [QxMD MEDLINE Link].
Rahimi RS, Rockey DC. Hepatic encephalopathy: pharmacological therapies targeting ammonia. Semin Liver Dis. 2016 Feb. 36(1):48-55. [QxMD MEDLINE Link].
Patidar KR, Bajaj JS. Covert and overt hepatic encephalopathy: diagnosis and management. Clin Gastroenterol Hepatol. 2015 Nov. 13(12):2048-61. [QxMD MEDLINE Link].
Pockros P, Hassanein T, Vierling J, et al. Phase 2, multicenter, randomized study of AST-120 (spherical carbon adsorbent) vs. lactulose in the treatment of lowgrade hepatic encephalopathy. J Hepatol. 2009. 50(Suppl 1):S43-4.
Simon-Talero M, Garcia-Martinez R, Torrens M, et al. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. J Hepatol. 2013 Dec. 59(6):1184-92. [QxMD MEDLINE Link].
Laleman W, Simon-Talero M, Maleux G, et al. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology. 2013 Jun. 57(6):2448-57. [QxMD MEDLINE Link].
Amaral OB, Quevedo J, Walz R, et al. Flumazenil and hepatic encephalopathy. Hepatology. 1999 Apr. 29(4):1338-9. [QxMD MEDLINE Link].
Amodio P, Del Piccolo F, Marchetti P, et al. Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology. 1999 Jun. 29(6):1662-7. [QxMD MEDLINE Link].
Avallone R, Zeneroli ML, Venturini I, et al. Endogenous benzodiazepine-like compounds and diazepam binding inhibitor in serum of patients with liver cirrhosis with and without overt encephalopathy. Gut. 1998 Jun. 42(6):861-7. [QxMD MEDLINE Link].
Bansky G, Meier PJ, Riederer E, et al. Effects of the benzodiazepine receptor antagonist flumazenil in hepatic encephalopathy in humans. Gastroenterology. 1989 Sep. 97(3):744-50. [QxMD MEDLINE Link].
Barbaro G, Di Lorenzo G, Soldini M, et al. Flumazenil for hepatic coma in patients with liver cirrhosis: an Italian multicentre double-blind, placebo-controlled, crossover study. Eur J Emerg Med. 1998 Jun. 5(2):213-8. [QxMD MEDLINE Link].
Basile AS, Jones EA. Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy. Hepatology. 1997 Jun. 25(6):1303-5. [QxMD MEDLINE Link].
Bianchi GP, Marchesini G, Fabbri A, et al. Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross-over comparison. J Intern Med. 1993 May. 233(5):385-92. [QxMD MEDLINE Link].
Bickford RG, Butt HR. Hepatic coma: the electroencephalographic pattern. J Clin Invest. 1955 Jun. 34(6):790-9. [QxMD MEDLINE Link]. [Full Text].
Bircher J, Buhrer M, Franz K, et al. [1st use of lactitol in the treatment of porto-systemic encephalopathy]. Schweiz Med Wochenschr. 1982 Sep 18. 112(38):1306-7. [QxMD MEDLINE Link].
Bresci G, Parisi G, Banti S. Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment. Eur J Med. 1993 Aug-Sep. 2(7):414-6. [QxMD MEDLINE Link].
Butterworth RF. Pathogenesis of acute hepatic encephalopathy. Digestion. 1998 Jul. 59 Suppl 2:16-21. [QxMD MEDLINE Link].
Chan H, Hazell AS, Desjardins P. Neurotoxins generated in liver failure cause altered expression of genes coding for key astrocytic proteins. Hepatology. 1999. 30(4):234A.
Charlton MR. Branched chains revisited. Gastroenterology. 1996 Jul. 111(1):252-5. [QxMD MEDLINE Link].
Child CG 3rd. Ligature of the portal vein (translation of original by Eck, 1877). Surg Gynecol Obstet. 1953. 375-6.
Conn HO. Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis. 1977 Jun. 22(6):541-50. [QxMD MEDLINE Link].
Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology. 1977 Apr. 72(4 Pt 1):573-83. [QxMD MEDLINE Link].
Costa E, Guidotti A. Diazepam binding inhibitor (DBI): a peptide with multiple biological actions. Life Sci. 1991. 49(5):325-44. [QxMD MEDLINE Link].
Cordoba J, Minguez B. Hepatic encephalopathy. Semin Liver Dis. 2008 Feb. 28(1):70-80. [QxMD MEDLINE Link].
Dasani BM, Sigal SH, Lieber CS. Analysis of risk factors for chronic hepatic encephalopathy: the role of Helicobacter pylori infection. Am J Gastroenterol. 1998 May. 93(5):726-31. [QxMD MEDLINE Link].
de Bruijn KM, Blendis LM, Zilm DH, et al. Effect of dietary protein manipulation in subclinical portal-systemic encephalopathy. Gut. 1983 Jan. 24(1):53-60. [QxMD MEDLINE Link].
Deschenes M, Dufresne MP, Bui B, et al. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites. Am J Gastroenterol. 1999 May. 94(5):1361-5. [QxMD MEDLINE Link].
Eck NV. Ligature of the portal vein. Voen Med J St-Petersburg (Russo). 1877. 130:1-2.
Elkington SG, Floch MH, Conn HO. Lactulose in the treatment of chronic portal-systemic encephalopathy. A double-blind clinical trial. N Engl J Med. 1969 Aug 21. 281(8):408-12. [QxMD MEDLINE Link].
Fabbri A, Magrini N, Bianchi G, et al. Overview of randomized clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalopathy. JPEN J Parenter Enteral Nutr. 1996 Mar-Apr. 20(2):159-64. [QxMD MEDLINE Link].
Felipo V, Hermenegildo C, Montoliu C, et al. Neurotoxicity of ammonia and glutamate: molecular mechanisms and prevention. Neurotoxicology. 1998 Aug-Oct. 19(4-5):675-81. [QxMD MEDLINE Link].
Ferenci P. Hepatic encephalopathy. McIntyre N, Benhamou JP, Bircher J, Rizzetto M, Rodes J, eds. Textbook of Clinical Hepatology. Oxford, England: Oxford University Press; 1991. Vol 1: 473-83.
Fischer JE, Baldessarini RJ. False neurotransmitters and hepatic failure. Lancet. 1971 Jul 10. 2(7715):75-80. [QxMD MEDLINE Link].
Flannery DB, Hsia YE, Wolf B. Current status of hyperammonemic syndromes. Hepatology. 1982 Jul-Aug. 2(4):495-506. [QxMD MEDLINE Link].
Genesca J, Gonzalez A, Segura R, et al. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis. Am J Gastroenterol. 1999 Jan. 94(1):169-77. [QxMD MEDLINE Link].
Germain L, Frexinos J, Louis A, et al. [Double blind study of lactulose in 8 patients with chronic hepatic encephalopathy after portocaval shunt]. Arch Fr Mal App Dig. 1973 Jun. 62(4):293-302. [QxMD MEDLINE Link].
Girard G, Butterworth RF. Effect of portacaval anastomosis on glutamine synthetase activities in liver, brain, and skeletal muscle. Dig Dis Sci. 1992 Jul. 37(7):1121-6. [QxMD MEDLINE Link].
Gitlin N. Hepatic encephalopathy. Zakim D, Boyer T, eds. Hepatology: a textbook of liver disease. 3rd ed. Philadelphia, Pa: WB Saunders; 1996. Vol 1: 605-17.
Groeneweg M, Gyr K, Amrein R, et al. Effect of flumazenil on the electroencephalogram of patients with portosystemic encephalopathy. Results of a double blind, randomised, placebo-controlled multicentre trial. Electroencephalogr Clin Neurophysiol. 1996 Jan. 98(1):29-34. [QxMD MEDLINE Link].
Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology. 1993 Nov. 18(5):1139-43. [QxMD MEDLINE Link].
Hassanein TI, Tofteng F, Brown RS Jr, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology. 2007 Dec. 46(6):1853-62. [QxMD MEDLINE Link].
Haussinger D, Laubenberger J, vom Dahl S, et al. Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy. Gastroenterology. 1994 Nov. 107(5):1475-80. [QxMD MEDLINE Link].
Hazell AS, Desjardins P, Butterworth RF. Chronic exposure of rat primary astrocyte cultures to manganese results in increased binding sites for the 'peripheral-type' benzodiazepine receptor ligand 3H-PK 11195. Neurosci Lett. 1999 Aug 13. 271(1):5-8. [QxMD MEDLINE Link].
Howard ER. Encephalopathy without cirrhosis: hunt the shunt. Gut. 1999 Sep. 45(3):329-30. [QxMD MEDLINE Link].
Haussinger D. Hepatic glutamine transport and metabolism. Adv Enzymol Relat Areas Mol Biol. 1998. 72:43-86. [QxMD MEDLINE Link].
Haussinger D. Low grade cerebral edema and the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology. 2006 Jun. 43(6):1187-90. [QxMD MEDLINE Link].
Ito S, Miyaji H, Azuma T, et al. Hyperammonaemia and Helicobacter pylori. Lancet. 1995 Jul 8. 346(8967):124-5. [QxMD MEDLINE Link].
Jalan R, Olde Damink SW, Hayes PC, et al. Diagnosis of hepatic encephalopathy: will in vivo proton MRS play a role?. Hepatology. 1999 May. 29(5):1605-7. [QxMD MEDLINE Link].
Jenkins RL, Gedaly R, Pomposelli JJ, et al. Distal splenorenal shunt: role, indications, and utility in the era of liver transplantation. Arch Surg. 1999 Apr. 134(4):416-20. [QxMD MEDLINE Link].
Kale RA, Gupta RK, Saraswat VA, et al. Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy. Hepatology. 2006 Apr. 43(4):698-706. [QxMD MEDLINE Link].
Keeling PW, Jones RB, Hilton PJ, et al. Reduced leucocyte zinc in liver disease. Gut. 1980 Jul. 21(7):561-4. [QxMD MEDLINE Link].
Kircheis G, Nilius R, Held C, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology. 1997 Jun. 25(6):1351-60. [QxMD MEDLINE Link].
Kircheis G, Quack G, Erbler H. L-ornithine L-aspartate in the treatment of hyperammonemia and hepatic encephalopathy. Conn HO, Bircher J, eds. Hepatic encephalopathy: syndromes and therapies. Bloomington, Ill: Medi-Ed; 1994. 373-83.
Kullmann F, Hollerbach S, Holstege A, et al. Subclinical hepatic encephalopathy: the diagnostic value of evoked potentials. J Hepatol. 1995 Jan. 22(1):101-10. [QxMD MEDLINE Link].
Kostler H. Proton magnetic resonance spectroscopy in portal-systemic encephalopathy. Metab Brain Dis. 1998 Dec. 13(4):291-301. [QxMD MEDLINE Link].
Larsen FS, Ejlersen E, Clemmesen JO. Preservation of cerebral oxidative metabolism in fulminant hepatic failure: an autoregulation study. Liver Transpl Surg. 1996 Sep. 2(5):348-53. [QxMD MEDLINE Link].
Larsen FS, Olsen KS, Ejlersen E, et al. Cerebral blood flow autoregulation and transcranial Doppler sonography in patients with cirrhosis. Hepatology. 1995 Sep. 22(3):730-6. [QxMD MEDLINE Link].
Lata J, Hulek P, Fejfar T, et al. [Rifaximin in the treatment of hepatic encephalopathy]. Vnitr Lek. 2002 Jun. 48(6):578-82. [QxMD MEDLINE Link].
Laubenberger J, Haussinger D, Bayer S, et al. Proton magnetic resonance spectroscopy of the brain in symptomatic and asymptomatic patients with liver cirrhosis. Gastroenterology. 1997 May. 112(5):1610-6. [QxMD MEDLINE Link].
Layrargues GP, Rose C, Spahr L, et al. Role of manganese in the pathogenesis of portal-systemic encephalopathy. Metab Brain Dis. 1998 Dec. 13(4):311-7. [QxMD MEDLINE Link].
Lee FY, Lu RH, Tsai YT, et al. Plasma interleukin-6 levels in patients with cirrhosis. Relationship to endotoxemia, tumor necrosis factor-alpha, and hyperdynamic circulation. Scand J Gastroenterol. 1996 May. 31(5):500-5. [QxMD MEDLINE Link].
Lee JH, Seo DW, Lee YS, et al. Proton magnetic resonance spectroscopy (1H-MRS) findings for the brain in patients with liver cirrhosis reflect the hepatic functional reserve. Am J Gastroenterol. 1999 Aug. 94(8):2206-13. [QxMD MEDLINE Link].
Lockwood AH. Early detection and treatment of hepatic encephalopathy. Curr Opin Neurol. 1998 Dec. 11(6):663-6. [QxMD MEDLINE Link].
Lockwood AH, Yap EW, Rhoades HM, et al. Altered cerebral blood flow and glucose metabolism in patients with liver disease and minimal encephalopathy. J Cereb Blood Flow Metab. 1991 Mar. 11(2):331-6. [QxMD MEDLINE Link].
Lockwood AH, Yap EW, Wong WH. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab. 1991 Mar. 11(2):337-41. [QxMD MEDLINE Link].
Loguercio C, Abbiati R, Rinaldi M, et al. Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol. 1995 Jul. 23(1):39-46. [QxMD MEDLINE Link].
Manzoni O, Prezeau L, Marin P, et al. Nitric oxide-induced blockade of NMDA receptors. Neuron. 1992 Apr. 8(4):653-62. [QxMD MEDLINE Link].
Mas A, Rodes J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol. 2003 Jan. 38(1):51-8. [QxMD MEDLINE Link].
Mehndiratta MM, Sood GK, Sarin SK, et al. Comparative evaluation of visual, somatosensory, and auditory evoked potentials in the detection of subclinical hepatic encephalopathy in patients with nonalcoholic cirrhosis. Am J Gastroenterol. 1990 Jul. 85(7):799-803. [QxMD MEDLINE Link].
Mendenhall CL, Rouster S, Marshall L, et al. A new therapy for portal systemic encephalopathy. Am J Gastroenterol. 1986 Jul. 81(7):540-3. [QxMD MEDLINE Link].
Michalopoulos GK, DeFrances MC. Liver regeneration. Science. 1997 Apr 4. 276(5309):60-6. [QxMD MEDLINE Link].
Montague PR, Gancayco CD, Winn MJ, et al. Role of NO production in NMDA receptor-mediated neurotransmitter release in cerebral cortex. Science. 1994 Feb 18. 263(5149):973-7. [QxMD MEDLINE Link].
Moore JW, Dunk AA, Crawford JR, et al. Neuropsychological deficits and morphological MRI brain scan abnormalities in apparently healthy non-encephalopathic patients with cirrhosis. A controlled study. J Hepatol. 1989 Nov. 9(3):319-25. [QxMD MEDLINE Link].
Moorman AF, Vermeulen JL, Charles R, et al. Localization of ammonia-metabolizing enzymes in human liver: ontogenesis of heterogeneity. Hepatology. 1989 Mar. 9(3):367-72. [QxMD MEDLINE Link].
Morgan MH, Read AE, Speller DC. Treatment of hepatic encephalopathy with metronidazole. Gut. 1982 Jan. 23(1):1-7. [QxMD MEDLINE Link].
Morgan MY. Cerebral magnetic resonance imaging in patients with chronic liver disease. Metab Brain Dis. 1998 Dec. 13(4):273-90. [QxMD MEDLINE Link].
Morgan MY, Jakobovits AW, James IM, et al. Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy. Gastroenterology. 1980 Apr. 78(4):663-70. [QxMD MEDLINE Link].
Mullen KD, Szauter KM, Kaminsky-Russ K. "Endogenous" benzodiazepine activity in body fluids of patients with hepatic encephalopathy. Lancet. 1990 Jul 14. 336(8707):81-3. [QxMD MEDLINE Link].
Ong J, Kerr DI. Clinical potential of GABAB receptor modulators. CNS Drug Rev. 2005 Autumn. 11(3):317-34. [QxMD MEDLINE Link].
Perney P, Butterworth RF, Mousseau DD, et al. Plasma and CSF benzodiazepine receptor ligand concentrations in cirrhotic patients with hepatic encephalopathy: relationship to severity of encephalopathy and to pharmaceutical benzodiazepine intake. Metab Brain Dis. 1998 Sep. 13(3):201-10. [QxMD MEDLINE Link].
Pogun S, Dawson V, Kuhar MJ. Nitric oxide inhibits 3H-glutamate transport in synaptosomes. Synapse. 1994 Sep. 18(1):21-6. [QxMD MEDLINE Link].
Pomier-Layrargues G. TIPS and hepatic encephalopathy. Semin Liver Dis. 1996 Aug. 16(3):315-20. [QxMD MEDLINE Link].
Pomier-Layrargues G, Giguere JF, Lavoie J, et al. Flumazenil in cirrhotic patients in hepatic coma: a randomized double-blind placebo-controlled crossover trial. Hepatology. 1994 Jan. 19(1):32-7. [QxMD MEDLINE Link].
Quero JC, Hartmann IJ, Meulstee J, et al. The diagnosis of subclinical hepatic encephalopathy in patients with cirrhosis using neuropsychological tests and automated electroencephalogram analysis. Hepatology. 1996 Sep. 24(3):556-60. [QxMD MEDLINE Link].
Rao VL, Butterworth RF. Neuronal nitric oxide synthase and hepatic encephalopathy. Metab Brain Dis. 1998 Sep. 13(3):175-89. [QxMD MEDLINE Link].
Read AE, McCarthy CF, Heaton KW, et al. Lactobacillus acidophilus (enpac) in treatment of hepatic encephalopathy. Br Med J. 1966 May 21. 1(5498):1267-9. [QxMD MEDLINE Link].
Riggio O, Efrati C, Catalano C, et al. High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study. Hepatology. 2005 Nov. 42(5):1158-65. [QxMD MEDLINE Link].
Riggio O, Masini A, Efrati C, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol. 2005 May. 42(5):674-9. [QxMD MEDLINE Link].
Riggio O, Merlli M, Pedretti G, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors. Dig Dis Sci. 1996 Mar. 41(3):578-84. [QxMD MEDLINE Link].
Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med. 1997 Aug 14. 337(7):473-9. [QxMD MEDLINE Link].
Rose C, Butterworth RF, Zayed J, et al. Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. Gastroenterology. 1999 Sep. 117(3):640-4. [QxMD MEDLINE Link].
Rose C, Michalak A, Pannunzio P, et al. L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action. Metab Brain Dis. 1998 Jun. 13(2):147-57. [QxMD MEDLINE Link].
Sandford SL, Tarter RE, Sclabassi R, et al. Sensory information processing in patients with nonalcoholic cirrhosis. Short-latency visual, auditory, and somatosensory event-related potentials. J Neurol Sci. 1987 Sep. 80(2-3):269-76. [QxMD MEDLINE Link].
Sanyal AJ, Freedman AM, Shiffman ML, et al. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. Hepatology. 1994 Jul. 20(1 Pt 1):46-55. [QxMD MEDLINE Link].
Schumacher IK, Okamoto T, Kim BH, et al. Transplantation of conditionally immortalized hepatocytes to treat hepatic encephalopathy. Hepatology. 1996 Aug. 24(2):337-43. [QxMD MEDLINE Link].
Stauch S, Kircheis G, Adler G, et al. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol. 1998 May. 28(5):856-64. [QxMD MEDLINE Link].
Strauss E, Tramote R, Silva EP, et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology. 1992 Dec. 39(6):542-5. [QxMD MEDLINE Link].
Sushma S, Dasarathy S, Tandon RK, et al. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology. 1992 Jul. 16(1):138-44. [QxMD MEDLINE Link].
Taylor-Robinson SD, Oatridge A, Hajnal JV, et al. MR imaging of the basal ganglia in chronic liver disease: correlation of T1-weighted and magnetisation transfer contrast measurements with liver dysfunction and neuropsychiatric status. Metab Brain Dis. 1995 Jun. 10(2):175-88. [QxMD MEDLINE Link].
Unseld E, Krishna DR, Fischer C, et al. Detection of desmethyldiazepam and diazepam in brain of different species and plants. Biochem Pharmacol. 1989 Aug 1. 38(15):2473-8. [QxMD MEDLINE Link].
Uribe M, Garcia-Ramos G, Ramos M, et al. Standard and higher doses of bromocriptine for severe chronic portal-systemic encephalopathy. Am J Gastroenterol. 1983 Aug. 78(8):517-22. [QxMD MEDLINE Link].
Van der Rijt CC, Schalm SW, De Groot GH, et al. Objective measurement of hepatic encephalopathy by means of automated EEG analysis. Electroencephalogr Clin Neurophysiol. 1984 May. 57(5):423-6. [QxMD MEDLINE Link].
Weissenborn K, Kolbe H. The basal ganglia and portal-systemic encephalopathy. Metab Brain Dis. 1998 Dec. 13(4):261-72. [QxMD MEDLINE Link].
Weissenborn K, Scholz M, Hinrichs H, et al. Neurophysiological assessment of early hepatic encephalopathy. Electroencephalogr Clin Neurophysiol. 1990 Apr. 75(4):289-95. [QxMD MEDLINE Link].
Yen CL, Liaw YF. Somatosensory evoked potentials and number connection test in the detection of subclinical hepatic encephalopathy. Hepatogastroenterology. 1990 Jun. 37(3):332-4. [QxMD MEDLINE Link].
Yurdaydin C, Karavelioglu D, Onaran O, et al. Opioid receptor ligands in human hepatic encephalopathy. J Hepatol. 1998 Nov. 29(5):796-801. [QxMD MEDLINE Link].
Zullo A, Rinaldi V, Meddi P, et al. Helicobacter pylori infection, plasma ammonia levels, and psychometric testing in cirrhotic patients. Am J Gastroenterol. 1999 Aug. 94(8):2214-8. [QxMD MEDLINE Link].
Li Y, He X, Pang H. A model to predict early hepatic encephalopathy in patients undergoing transjugular intrahepatic portosystemic shunt. Turk J Gastroenterol. 2019 Aug. 30(8):702-7. [QxMD MEDLINE Link]. [Full Text].